Effectiveness of Antipsychotic Treatments for Schizophrenia: Interim 6-Month Analysis From a Prospective Observational Study (IC-SOHO) Comparing Olanzapine, Quetiapine, Risperidone, and Haloperidol

Dossenbach, Martin; Erol, Almila; Kessaci, Mohand el Mahfoud; Shaheen, Mostafa O.; Sunbol, Mohammed M.; Boland, Jason; Hodge, Andrew; O'Halloran, Ruth A.; Bitter, Istvan; IC-SOHO Study Group

doi:10.4088/jcp.v65n0305

Cited by 80Schizophrenia research and treatmentMental Health and PsychiatryBipolar Disorder and Treatment

Effectiveness of Antipsychotic Treatments for Schizophrenia: Interim 6-Month Analysis From a Prospective Observational Study (IC-SOHO) Comparing Olanzapine, Quetiapine, Risperidone, and Haloperidol

Dossenbach, Martin, Erol, Almila, Kessaci, Mohand el Mahfoud, Shaheen, Mostafa O., Sunbol, Mohammed M., Boland, Jason, Hodge, Andrew, O'Halloran, Ruth A. +2 more·2004·The Journal of Clinical Psychiatry

DOI 10.4088/jcp.v65n0305

Open this paper in CoChat — free account

Abstract

BACKGROUND: The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study was designed to provide information regarding use and outcome of antipsychotic treatments in a large, diverse population in real practice settings. METHOD: Outpatients with schizophrenia (ICD-10 or DSM-IV) who initiated or changed to a new antipsychotic entered this 3-year, naturalistic, prospective observational study. Four monotherapy treatment groups were defined according to the antipsychotic prescribed at baseline, namely olanzapine, risperidone, quetiapine, and haloperidol. Efficacy was assessed using the Clinical Global Impressions-Severity of Illness rating scale (CGI-S), inclusive of subscales for positive, negative, depressive, and cognitive symptoms. Tolerability was assessed by adverse event questionnaires and weight measurements. Six-month findings are described. RESULTS: At baseline, 5833 participants were prescribed monotherapy and the mean severity of illness was moderate to marked (CGI-S). At 6 months, olanzapine resulted in significantly greater improvements in overall, positive, negative, depressive, and cognitive symptoms compared with quetiapine, risperidone or haloperidol (p <.001). Improvements in overall, negative, and cognitive symptoms were significantly higher for risperidone compared with haloperidol (p <.001), whereas improvements across all symptoms were comparable for quetiapine and haloperidol. Extra-pyramidal symptoms and tardive dyskinesia decreased compared with baseline in the olanzapine, quetiapine, and risperidone groups but increased in the haloperidol group (p <.001, likelihood of extrapyramidal symptoms with haloperidol compared with olanzapine, quetiapine, or risperidone). Sexual function adverse events were most prominent in the haloperidol and risperidone treatment groups. Weight change was significantly greater for olanzapine compared with the other antipsychotics (p <.001). CONCLUSION: Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia.

Integrity signals

Registry

Crossref · 10.4088/jcp.v65n0305

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Only few studies have directly compared the sexual functioning associated with different atypical antipsychotics.
“To date, only few studies (534-547) have directly compared the sexual functioning associated with different atypical AP.”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [543]

Sorted by citations

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Incidence of Tardive Dyskinesia With Atypical Versus Conventional Antipsychotic Medications
Woods, S. W., Morgenstern, H., Saksa, J. R., Walsh, B. C., Sullivan, M. C., Money, R. W., Hawkins, K. A., Gueorguieva, R. V., & Glazer, W. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03890yel · Cited by 186 · see citing works
Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia
Kinon, B. J., Chen, L., Ascher‐Svanum, H., Stauffer, V. L., Kollack‐Walker, S., Zhou, W., Kapur, S., & Kane, J. M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.164 · Cited by 182 · see citing works
The Relative Sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials
Leucht, S., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300873 · Cited by 154 · see citing works
“It has already been successfully used as a sole measure in a large prospective observational study in which clear efficacy differences between antipsychotics were found (Dossenbach et al, 2004).”
Method
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
Dossenbach, M., Dyachkova, Y., Pirildar, S., Anders, M., Khalil, A., Araszkiewicz, A., Shakhnovich, T., Akram, A., Pecenak, J., McBride, M., et al. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.005 · Cited by 121 · see citing works
Self-citation
Psychopharmacology of Aggression in Children and Adolescents with Autism: A Critical Review of Efficacy and Tolerability
Parikh, M. S., Kolevzon, A. L., & Hollander, E. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0041 · Cited by 121 · see citing works
“According to studies in adult populations with schizophrenia, risperidone also has a lower risk of EPS and tardive dyskinesia (Dossenbach et al. 2004; Schooler et al. 2005).”
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
Ascher‐Svanum, H., Zhu, B., Faries, D. E., Landbloom, R. P., Swartz, M. S., & Swanson, J. W. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-8 · Cited by 110 · see citing works
“Furthermore, our core findings on differential effectiveness between typicals and atypicals are highly consistent with those found in prior RCTs [9- 11,15,42], in retrospective claims database studies [4,21,43,44], and in naturalistic prospective studies [4, 30- 33 ,40].”
BackgroundMethodResultInfluential
Sexual dysfunction in patients with schizophrenia on antipsychotic medication
Üçok, A., İncesu, C., Aker, T., & Erkoç, Ş. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.01.001 · Cited by 104 · see citing works
“On the other hand, a recent report stated that psychiatrists significantly underestimate the presence of SD despite patient complaints [12].”
Background
Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?
Becker, T. M., & Kilian, R. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00711.x · Cited by 99 · see citing works
Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood
Saeedi, H., Remington, G., & Christensen, B. K. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.033 · Cited by 89 · see citing works
Antipsychotic-Induced Sexual Dysfunction and Its Management
Park, Y. W., Kim, Y., & Lee, J. H. (2012) · The World Journal of Men s Health · doi:10.5534/wjmh.2012.30.3.153 · Cited by 86 · see citing works
Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data
Savill, M., Banks, C., Khanom, H., & Priebe, S. (2014) · Psychological Medicine · doi:10.1017/s0033291714002712 · Cited by 72 · see citing works
Randomized, Double-blind 6-Month Comparison of Olanzapine and Quetiapine in Patients With Schizophrenia or Schizoaffective Disorder With Prominent Negative Symptoms and Poor Functioning
Kinon, B. J., Noordsy, D. L., Liu‐Seifert, H., Gulliver, A. H., Ascher‐Svanum, H., & Kollack‐Walker, S. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000236658.16286.25 · Cited by 73 · see citing works
Effectiveness studies: advantages and disadvantages
Möller, H. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/hmoeller · Cited by 69 · see citing works
Strategies for improving adherence to second generation antipsychotics in patients with schizophrenia by increasing ease of use
BURTON, S. C. (2005) · Journal of Psychiatric Practice · doi:10.1097/00131746-200511000-00003 · Cited by 68 · see citing works
Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients*
Karagianis, J. L., Novick, D., Pečeňák, J., Haro, J. M., Dossenbach, M. R. K., Treuer, T., Montgomery, W. S., Walton, R., & Lowry, A. J. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02191.x · Cited by 68 · see citing works
Self-citation
Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
Ascher‐Svanum, H. (2008) · Patient Preference and Adherence · doi:10.2147/ppa.s2940 · Cited by 65 · see citing works
“…quetiapine, ziprasi-done, and aripiprazole (PhRMA aripiprazole; Gilbody et al 2000; Ren et al 2002; Bagnall et al 2003; Santarlasci and Messori 2003; Dossenbach et al 2004; Pelagotti et al 2004; Simpson et al 2004; Breier et al 2005; Mudge et al 2005; Kinon et al 2006a, b; Tunis et al 2006;…”
Influential
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO)
Bitter, I., Czobor, P., Dossenbach, M. R. K., et al. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.01.009 · Cited by 64 · see citing works
“1 resulted in a reduced subject sample in comparison with the numbers published by Dossenbach et al. (2004).”
BackgroundResultSelf-citation
Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial
Joffe, G., Terevnikov, V., Joffe, M., Stenberg, J., Burkin, M. M., & Tiihonen, J. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.12.002 · Cited by 63 · see citing works
Extrapyramidal side effects with atypical neuroleptics in bipolar disorder
Ghaemi, S. N., Hsu, D. J., Rosenquist, K. J., Pardo, T. B., & Goodwin, F. K. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.014 · Cited by 62 · see citing works
Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial
Tunis, S. L., Faries, D. E., Nyhuis, A. W., et al. (2005) · Value in Health · doi:10.1111/j.1524-4733.2006.00083.x · Cited by 53 · see citing works
Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine
Verachai, V., Rukngan, W., Chawanakrasaesin, K., Nilaban, S., Suwanmajo, S., Thanateerabunjong, R., Kaewkungwal, J., & Kalayasiri, R. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3485-6 · Cited by 52 · see citing works
“It is known that second-generation antipsychotics have lower extrapyramidal side effects compared to haloperidol (Dossenbach et al. 2004; McIntyre et al. 2005), although our study precluded such a conclusion partly due to the low dose of the antipsychotics and the short duration of the study.”
Result
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
Furiak, N. M., Ascher‐Svanum, H., Klein, R. W., Smolen, L. J., Lawson, A. H., Montgomery, W. S., & Conley, R. R. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.554533 · Cited by 51 · see citing works
A 6-Month Prospective Observational Study on the Effects of Quetiapine on Sexual Functioning
Montejo, A. L., Rico‐Villademoros, F., Tafalla, M., & Majadas, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186872.04984.56 · Cited by 48 · see citing works
“8%, a rate similar to that of previous prospective studies (16%–18%).(9,18) In addition, and although it is beyond the scope of this study, the improvement of sexual functioning observed in our study also suggests that switching to quetiapine could be a suitable alternative for treating antipsychotic-induced SD.”
Result
Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review
Binder, M. D., Detraux, J., & Peuskens, J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.906579 · Cited by 47 · see citing works
“[140] Loss of libido (% of subjects) 41 28{ Impotence/SD (% of subjects) 27 19{ Amenorrhea/menstrual disturbances (% of subjects) 28 17{”
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
Furiak, N. M., Ascher‐Svanum, H., Klein, R. W., Smolen, L. J., Lawson, A. H., Conley, R. R., & Culler, S. D. (2009) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-7-4 · Cited by 45 · see citing works
Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach
Montejo, Á., de Alarcón, R., Prieto, N., Acosta, J., Buch, B., & Montejo, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020308 · Cited by 40 · see citing works
Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations
Möller, H., & Maier, W. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0070-9 · Cited by 36 · see citing works
“This means that evidence for efficacy and tolerability should be obtained from phase IV studies, which are more closely oriented towards routine clinical care [7, 8, 40, 73, 74, 123], to complement the”
Background
Relative association of treatment‐emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3‐year observational study
Adrianzén, C., Arango-Dávila, C. A., Martínez-Araujo, D., Ruiz, I. D. L. R., Walton, R., Dossenbach, M. R. K., & Karagianis, J. L. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1143 · Cited by 36 · see citing works
“The European (Haro et al., 2003a) and Intercontinental (Dossenbach et al., 2004) Schizophrenia Outpatient Health Outcomes (SOHO) studies are large, multinational, observational and naturalistic studies of health outcomes associated with antipsychotic medication in patients with schizophrenia.”
BackgroundMethodInfluentialSelf-citation
The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy
Montgomery, W. S., Liu, Ascher‐Svanum, H., Xue, Treuer, T., & Stensland, M. D. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s44325 · Cited by 34 · see citing works
“67,70 However, FGAs and SGAs are heterogeneous groups of medications that have been somewhat arbitrarily grouped together primarily as a result of being developed before or after clozapine.”
Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data
Yoshida, K., Bies, R. R., Suzuki, T., Remington, G. J., Pollock, B. G., Mizuno, Y., Mimura, M., & Uchida, H. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.017 · Cited by 33 · see citing works
“…symptoms (EPS) of SGAs compared to conventional antipsychotics (Tollefson et al., 1997; Haro et al., 2003a, 2003b; Correll et al., 2004; Dossenbach et al., 2004; Tenback et al., 2005), it should be emphasized that the former agents still continue to carry a risk for tardive dyskinesia…”
Genetic Correlates of Olanzapine-Induced Weight Gain in Schizophrenia Subjects from North India: Role of Metabolic Pathway Genes
Srivastava, V., Deshpande, S. N., Nimgaonkar, V. L., Lerer, B., & Thelma, B. K. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.8.1055 · Cited by 31 · see citing works
Correlates of response to Olanzapine in a North Indian Schizophrenia sample
Thomas, P., Srivastava, V., Singh, A., Mathur, P., Nimgaonkar, V. L., Lerer, B., Thelma, B. K., & Deshpande, S. N. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.09.010 · Cited by 31 · see citing works
The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain
Ciudad, A., Haro, J. M., Alonso, J., Bousoño, M., Suarez, D. L., Novick, D., & Gilaberte, I. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.09.008 · Cited by 29 · see citing works
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden
Einarson, T. R., Vicente, C., Zilbershtein, R., Piwko, C., Bø, C. N., Pudas, H., Jensen, R., & Hemels, M. E. H. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2013.852243 · Cited by 28 · see citing works
Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America
Kasper, S. F., Lowry, A. J., Hodge, A. T., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.032 · Cited by 27 · see citing works
Self-citation
Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
Bitter, I., Treuer, T., Dyachkova, Y., et al. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.08.001 · Cited by 26 · see citing works
Self-citation
Towards a framework for treatment effectiveness in schizophrenia
Juckel, G., de Bartolomeis, A., Gorwood, P. A. P. M., Mosolov, S. N., Pani, L., Rossi, A., & Sanjuán, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s61672 · Cited by 23 · see citing works
“Verbal reports are largely used for the assessment of social skills; however, there is a large discrepancy between what patients say and what they actually do, as well as between the reports provided by patients and those of their caregivers or relatives.(17,65) If possible, personal and social functioning should be a…”
Region Specific Regulation of NR1 in Rhesus Monkeys Following Chronic Antipsychotic Drug Administration
O’Connor, J. A., Hasenkamp, W. M., Horman, B. M., Muly, E. C., & Hemby, S. E. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.044 · Cited by 20 · see citing works
The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat
Zhang, X., Zhang, Z., Cheng, W., Mou, X., & Reynolds, G. P. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106068702 · Cited by 19 · see citing works
“Sexual dysfunction induced by haloperidol has been demonstrated in several previous animal studies and clinical research (Pfaus and Phillips, 1991; Hummer et al., 1999; Tupala et al., 1999; Dossenbach et al., 2004).”
BackgroundResult
Overview of the findings from the European SOHO study
Suarez, D. L., & Haro, J. M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.6.873 · Cited by 19 · see citing works
Treatment-refractory schizophrenia
Buckley, P. F., & Shendarkar, N. (2005) · Current Opinion in Psychiatry · doi:10.1097/00001504-200503000-00010 · Cited by 17 · see citing works
Drug Class Review: Atypical Antipsychotic Drugs
McDonagh, M. S., Peterson, K., Carson, S., Fu, R., & Thakurta, S. (2010) · Cited by 14 · see citing works
Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial
Kilian, R., Steinert, T., Schepp, W., Weiser, P., Jaeger, S., Pfiffner, C., Frasch, K., Eschweiler, G. W., Messer, T., Croissant, D., et al. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0316-9 · Cited by 14 · see citing works
“Random-effects regression analyses were performed by means of the xtreg module of STATA 11 for Windows.”
MethodInfluential
A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia
Pérez, V., Cañas, F., & Tafalla, M. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f47c44 · Cited by 14 · see citing works
“A similar approach has been used in other naturalistic, comparative studies in patients with schizophrenia (Bobes et al., 2003b; Dossenbach et al., 2004; Canas et al., 2005).”
Result
Olanzapine: a critical review of recent literature
Buckley, P. F. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.12.2077 · Cited by 14 · see citing works
“There are also several naturalistic studies of SGAs, including olanzapine [26], which informs us on the dosing and profile of SGAs in clinical practice.”
Background
Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
Liu‐Seifert, H., Ascher‐Svanum, H., Osuntokun, O. O., Jen, K. Y., & Gomez, J. C. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-87 · Cited by 13 · see citing works
“Furthermore, patients treated with olanzapine were consistently found to stay longer on treatment compared to those treated with haloperidol [23,31,44-49], risperidone [21,23,24,28, 48-56 ] and ziprasidone [21,27,57-59].”
Result
Assessment of Motivations and Willingness to Participate in Research of Outpatients With Anxiety, Mood, and Psychotic Disorders
Morán‐Sánchez, I., López, A. M., & Pérez-Cárceles, M. D. (2018) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/1556264618789564 · Cited by 11 · see citing works
“We hypothesized that prior positive drugs-switching experiences might encourage patients to try new medications with fewer side effects or increased therapeutic benefits (Dossenbach et al., 2004).”
Background
Belgian Schizophrenia Outcome Survey – Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol
Peuskens, J., Gillain, B., Graeve, D. D., Vleymen, B. V., & Albert, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.11.002 · Cited by 11 · see citing works
“Although previous studies have shown a higher risk in patients with haloperidol [7] and risperidone [7,14], other studies have shown similar risks with all three drugs [1].”
Result
Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
Ascher‐Svanum, H., Montgomery, B., McDonnell, D., Coleman, & Feldman, P. D. (2012) · International Journal of General Medicine · doi:10.2147/ijgm.s29052 · Cited by 10 · see citing works
Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO)
Treuer, T., Anders, M., Bitter, I., Dobre, G., Pečeňák, J., Dyachkova, Y., Harrison, G., & O'Mahoney, J. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500500409663 · Cited by 10 · see citing works
“Patients with a low body mass index (BMI) may have a greater propensity for weight gain than patients with higher BMIs [8,44], although a recent report found that overweight patients had a higher risk of clinically relevant weight gain than low or normal weight patients [43].”
BackgroundSelf-citation
The Effect of Chronic Antipsychotic Drug on Hypothalamic Expression of Neural Nitric Oxide Synthase and Dopamine D2 Receptor in the Male Rat
Zhang, X. R., Wang, Y. X., Zhang, Z. J., Li, L., & Reynolds, G. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033247 · Cited by 10 · see citing works
“The current study investigated the expression of neural NOS (nNOS) and the dopamine D2 receptor in the MPOA and PVN after chronic systemic administration of the typical antipsychotic haloperidol, and the atypical antipsychotics risperidone and quetiapine, in which haloperidol and risperidone, but not quetiapine are as…”
Background
Change in Framingham Risk Score in Patients With Schizophrenia
del Valle, M. C., Loebel, A. D., Murray, S., Yang, R., Harrison, D. J., & Cuffel, B. J. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0602 · Cited by 10 · see citing works
The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues
Zhang, X. R., Zhang, Z. J., Jenkins, T. A., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.10.002 · Cited by 9 · see citing works
Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study
Innamorati, M., Baratta, S., Vittorio, C. D., Lester, D., Girardi, P., Pompili, M., & Amore, M. (2013) · Schizophrenia Research and Treatment · doi:10.1155/2013/423205 · Cited by 10 · see citing works
Chinese version of the Psychotropic-related Sexual Dysfunction Questionnaire (PRSexDQ -SALSEX): Validity and reliability for schizophrenic patients taking antipsychotics
Wang, Y., Zhang, P., Xin, L.-M., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.05.063 · Cited by 9 · see citing works
Psychopathology, psychopharmacological properties, decision-making capacity to consent to clinical research and the willingness to participate among long-term hospitalized patients with schizophrenia
Wu, B.-J., Liao, H.-Y., Chen, H., & Lan, T. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.020 · Cited by 8 · see citing works
“This might be due to prior antipsychotic-switching experiences that gave patients a favorable response to trying atypical antipsychotics with fewer side effects or increased neurocognitive benefits (Dossenbach et al., 2004).”
Background
Pharmacotherapy Update: Risperidone in the Treatment of Schizophrenia
Raja, M. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1123 · Cited by 7 · see citing works
Drug-Induced Movement Disorders in Older Adults: An Overview for Clinical Practitioners
Detweiler, M. B., Kalafat, N., & Kim, K. Y. (2007) · The Consultant Pharmacist · doi:10.4140/tcp.n.2007.149 · Cited by 7 · see citing works
Antipsychotics Induced Reproductive Toxicity by Stimulating Oxidative Stress: A Comparative in Vivo and in Silico Study
Dinçer, B., Yazıcı, A. B., Çınar, İ., Toktay, E., Selli, J., Çadırcı, E., Bayraktutan, Z., & Yazıcı, E. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202201190 · Cited by 6 · see citing works
HALOPERIDOL VERSUS RISPERIDONE: A COMPARISON OF BENEFICIAL EFFECT ON COGNITIVE FUNCTION OF PATIENTS WITH CHRONIC SCHIZOPHRENIA
Abdolahian, E., Moharreri, F., & Bordbar, M. R. F. (2008) · Cited by 6 · see citing works
Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study
Treuer, T., Martényi, F., Şaylan, M., et al. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02331.x · Cited by 6 · see citing works
Schizophrenia Outpatient Health Outcomes study: twelve-month findings
Novick, D. (2012) · Pragmatic and Observational Research · doi:10.2147/por.s26552 · Cited by 5 · see citing works
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
Faries, D. E., Ascher‐Svanum, H., Phillips, G. A., Nyhuis, A. W., Sugihara, T., Stauffer, V. L., & Kinon, B. J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-142 · Cited by 5 · see citing works
“While there is research supporting the benefits of switching when warranted [22-24], others have challenged this notion [25].”
Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia
Ascher‐Svanum, H., Nyhuis, A. W., Faries, D. E., Heiler, L., & Kinon, B. J. (2008) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.2.3.4 · Cited by 5 · see citing works
NonParkinsonism Movement Disorders in the Elderly
Chen, J. J., & Lee, K. C. (2006) · The Consultant Pharmacist · doi:10.4140/tcp.n.2006.58 · Cited by 5 · see citing works
Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders
Yoshimura, Y., Takeda, T., Kishi, Y., Harada, T., Nomura, A., Washida, K., Yoshimura, B., Sato, K., Yada, Y., & Aoki, S. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000689 · Cited by 4 · see citing works
Evaluation antipsychotic medication choose retrospectively in inpatients with a diagnose of schizophrenia or schizoaffective disorder: 787 case
Yılmaz, A., Soykan, A., Gül, E. S., et al. (2007) · Psychiatry and Clinical Psychopharmacology · Cited by 4 · see citing works
Analysis of social class by LCA in patients with schizophrenia: change in psychopathology after 12-month of treatment -
Şaylan, M., Üçok, A., Uğuz, Ş., et al. (2009) · Psychiatry and Clinical Psychopharmacology · Cited by 3 · see citing works
Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
Lee, P., Kim, C. E., Kim, C. Y., Lin, W., Habil, H., Dyachkova, Y., Mcbride, M., & Dossenbach, M. R. K. (2008) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500801976634 · Cited by 1 · see citing works
“Patients participated from 27 countries throughout Africa, Asia, Central and Eastern Europe, Latin America, and the Middle East [24].”
BackgroundMethodInfluentialSelf-citation
Genetically Engineered Mice for Schizophrenia Research
Belforte, J. E., & Nakazawa, K. (2011) · Neuromethods · doi:10.1007/978-1-61779-157-4_10 · Cited by 1 · see citing works
Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial
Kane, J. M., Fleischhacker, W., Kolitsopoulos, F. M., Karayal, O. N., Geier, J. L., SIU, C. O., Reynolds, R., Faich, G. A., & Strom, B. L. (2012) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2012.224059
Funcionalidad, calidad de vida y uso de recursos de salud de olanzapina vs risperidona y antipsicóticos típicos: resultados de 3 años del estudio schizophrenia outpatient health outcomes (SOHO) en la región andina
Adrianzén, C., Dossenbach, M. R. K., & Leadbetter, M. (2007) · Repositorio Institucional Universidad El Bosque
Self-citation
Resultados clínicos de 3 años del estudio Schizophrenia Outpatients Health Outcomes (SOHO) en Argentina
Gargoloff, P., García-Bonetto, G. M., Galeno, R., et al. (2009) · Archivos de Neurociencias
World Psychiatryis indexed in PubMed, Current Contents/Clinical Medicine, Current Contents/Social and Behavioral Sciences, Science Citation Index, and EMBASE Âñåìèðíàÿ Ïñèõèàòðè÷åñêàÿ Àññîöèàöèÿ (ÂÏÀ)
Maj, M., Ïðåçèäåíò, È., Tasman, A., & Herrman, H. (2011)
Eficacia de la monoterapia de clozapina, olanzapina, quetiapina, risperidona y haloperidol en la reducción del comportamiento hostil y agresivo en pacientes ambulatorios tratados por esquizofrenia: un estudio naturalista prospectivo (IC-SOHO)
Bitter, I., Czobor, P., Dossenbach, M. R. K., et al. (2006) · European psychiatry (Ed Española) · doi:10.1017/s1134066500002988
Self-citation
Estudio SOHO (Variables Relacionadas con la Salud en Pacientes Ambulatorios con Esquizofrenia): resultados a los 3 años de la suspensión del tratamiento antipsicótico y factores clínicos relacionados con ella en España
Ciudad, A., Haro, J. M., Alonso, J., Bousoño, M., Suarez, D. L., Novick, D., & Gilaberte, I. (2008) · European psychiatry (Ed Española) · doi:10.1017/s1134066500005737
Disfunción sexual en pacientes con esquizofrenia tratados con antipsicóticos
Üçok, A., Incesu, C., Aker, T., & Erkoç, Ş. (2007) · European psychiatry (Ed Española) · doi:10.1017/s1134066500005129
Efectos de los tratamientos con antipsicóticos atípicos y típicos en la función sexual en los pacientes con esquizofrenia: resultados al año del Estudio Intercontinental de Evolución de la Salud de Pacientes Ambulatorios con Esquizofrenia (IC-SOHO)
Dossenbach, M. R. K., Dyachkova, Y., Pırıldar, Ş., Anders, M., Khalil, A. H., Araszkiewicz, A. S., Shakhnovich, T., Akram, A., Pečeňák, J., McBride, M., et al. (2006) · European psychiatry (Ed Española) · doi:10.1017/s1134066500003611
Self-citation
Current awareness in human psychopharmacology
(2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.632

Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
Tenback, D. E. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.8.1438 · Cited by 25 · see citing works
Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study
Tenback, D. E., van Harten, P. N., Slooff, C. J., van Os, J., & SOHO Study Group (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.8.1438 · Cited by 86 · see citing works
Long-term treatment of chronic schizophrenia with risperidone
Möller, H. ‐., Gagiano, C. A., Addington, D. E., et al. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199805000-00001 · Cited by 47 · see citing works
Tardive Dyskinesia in Elderly Patients: An Update
Goldberg, R. J. (2002) · Journal of the American Medical Directors Association · doi:10.1016/s1525-8610(04)70458-2 · Cited by 40 · see citing works
Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
Lindström, E., Eriksson, B., Hellgren, A., et al. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80105-7 · Cited by 105 · see citing works

Authors: Dossenbach, M., Erol, A., Kessaci, M. E. M., Shaheen, M. O., Sunbol, M. M., Boland, J., Hodge, A., O'Halloran, R. A., Bitter, I., & IC-SOHO Study Group
Affiliations: Eli Lilly (United States) (US)
Cairo University hospitals (EG)
Semmelweis University (HU)
ORCID: Dossenbach, Martin
Shaheen, Mostafa O.
Hodge, Andrew
Venue: The Journal of Clinical Psychiatry
Publisher: Physicians Postgraduate Press, Inc
Published: 2004-03-15
Volume: 65
Issue: 3
Pages: 312-321
ISSN: 0160-6689 (ISSN-L)
DOI: 10.4088/jcp.v65n0305
OpenAlex: W1965940175
Cited by: 80
References: 0
Citations by year: 2023: 1 · 2021: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2014: 5 · 2013: 3 · 2012: 7
FWCI: 5.97
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: schizophrenia, antipsychotic monotherapy, olanzapine, risperidone, quetiapine, haloperidol, atypical antipsychotics, treatment efficacy, symptom severity, extrapyramidal symptoms, tardive dyskinesia, weight gain, outpatients
MeSH terms: Quetiapine Fumarate, Olanzapine, Adult, Benzodiazepines, Cognition Disorders, Dibenzothiazepines, Dyskinesia, Drug-Induced, Female, Haloperidol, Humans, Hyperprolactinemia, Male, Prospective Studies, Surveys and Questionnaires, Schizophrenia, Severity of Illness Index, Sexual Dysfunction, Physiological, Antipsychotic Agents, Weight Gain, Risperidone, Observation, International Classification of Diseases, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of Antipsychotic Treatments for Schizophrenia: Interim 6-Month Analysis From a Prospective Observational Study (IC-SOHO) Comparing Olanzapine, Quetiapine, Risperidone, and Haloperidol

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cited by

Related

Record

About these checks